ICU Medical VP Sanzone sells 2,447 ICUI shares

ICU Medical Inc. executive reports stock sale.

Rhea-AI Filing Summary

ICU Medical Inc. executive reports stock sale. VP and General Counsel Virginia Ruth Sanzone sold 2,447 shares of ICU Medical common stock in an open-market sale at $124.08 per share. After this transaction, she directly holds 19,460 shares, so the sale represents a modest portion of her overall position.

Insights

Equity compensation and insider-trading analyst

ICU Medical’s general counsel made a modest open‑market share sale.

VP and General Counsel Virginia Ruth Sanzone sold 2,447 shares of ICU Medical common stock in an open-market transaction at $124.08 per share. Following the sale, she continues to hold 19,460 shares directly.

This is a discretionary open-market sale (transaction code S), not a tax withholding or option exercise. Based on the disclosed figures, the transaction represents a relatively small portion of her total holdings and appears routine in scale.

Insider Trade Summary

Net Seller: 2,447 shares

Net Sell 1 txn

Insider Sanzone Virginia Ruth

Role VP, General Counsel

Sold 2,447 shs ($304K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,447	$124.08	$304K

Holdings After Transaction: Common Stock — 19,460 shares (Direct)

Footnotes (1)

1. F1. All shares sold were sold at the exact price disclosed.

Key Figures

Shares sold: 2,447 shares Sale price per share: $124.08 per share Shares held after transaction: 19,460 shares +2 more

5 metrics

Shares sold 2,447 shares Open-market sale of ICU Medical common stock

Sale price per share $124.08 per share Price for each share sold in the transaction

Shares held after transaction 19,460 shares Direct holdings following the sale

Transaction code S Sale in open market or private transaction

Ownership type Direct (D) Direct ownership of the reported shares

Key Terms

open-market sale, Common Stock, transaction code S, direct ownership

4 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

transaction code S financial

"transaction_code: "S" with description "Sale in open market or private transaction""

direct ownership financial

"ownership_type: "direct" and ownership_code: "D""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ICU Medical (ICUI) disclose for Virginia Ruth Sanzone?

ICU Medical disclosed that VP and General Counsel Virginia Ruth Sanzone sold 2,447 shares of common stock in an open-market transaction. The shares were sold at $124.08 per share, and she retained 19,460 shares directly after the sale.

How many ICU Medical (ICUI) shares did the insider sell and at what price?

The insider sold 2,447 shares of ICU Medical common stock at $124.08 per share. This reflects a single open-market sale transaction reported on Form 4, with all shares sold at the exact disclosed price according to the filing footnote.

What are Virginia Ruth Sanzone’s ICU Medical (ICUI) holdings after the reported sale?

After the reported transaction, Virginia Ruth Sanzone directly holds 19,460 shares of ICU Medical common stock. The Form 4 indicates that these are direct holdings, and no remaining derivative securities are listed in the derivative summary for this filing.

Was the ICU Medical (ICUI) insider transaction an open-market sale or another type?

The transaction was an open-market sale of common stock, coded “S” on Form 4. The filing describes it as an open-market sale, with a footnote confirming that all shares were sold at the exact price of $124.08 per share disclosed.

Does ICU Medical’s (ICUI) Form 4 show any option exercises or derivative transactions?

No option exercises or derivative transactions are shown in this Form 4. The derivative summary lists no remaining derivative positions, and the only reported activity is the non-derivative common stock sale totaling 2,447 shares at $124.08 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 12:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sanzone Virginia Ruth

(Last) (First) (Middle)

951 CALLE AMANECER

(Street)

SAN CLEMENTE CALIFORNIA 92673

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ICU MEDICAL INC/DE [ ICUI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		S		2,447	D	$124.08(1)	19,460	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All shares sold were sold at the exact price disclosed.

	By: Paula Darbyshire, Attorney-in-Fact For: Virginia Sanzone	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)